HTG Molecular Diagnostics is a leading provider of molecular-based technology solutions for gene expression profiling, miRNA, siRNA and mRNA measurement for translational medicine and diagnostic applications. HTG’s product offerings have since expanded to include its HTG EdgeSeq product lines, which automate sample and targeted library preparation for next-generation sequencing. The Company's qNPA molecular technology platform is well-suited for reliably detecting small, yet important, changes in gene expression levels in a variety of sample types. 

TypePublic
HQTucson, US
Founded1997
Size (employees)87 (est)
Websitehtgmolecular.com
HTG Molecular Diagnostics was founded in 1997 and is headquartered in Tucson, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at HTG Molecular Diagnostics

Timothy TJ B. Johnson

Timothy TJ B. Johnson

CEO
John L. Lubniewski

John L. Lubniewski

President, Chief Operating Officer
Shaun D. McMeans

Shaun D. McMeans

Senior Vice President of Finance, Administration and Chief Financial Officer
Patrick Pat C. Roche

Patrick Pat C. Roche

Senior Vice President, Scientific and Medical Affairs
Sam M. Rua

Sam M. Rua

Senior Vice President of Regulatory Affairs and Quality Systems
Show more

HTG Molecular Diagnostics Office Locations

HTG Molecular Diagnostics has an office in Tucson
Tucson, US (HQ)
3430 E Global Loop
Show all (1)
Report incorrect company information

HTG Molecular Diagnostics Financials and Metrics

HTG Molecular Diagnostics Revenue

Embed Graph
HTG Molecular Diagnostics's revenue was reported to be $14.76 m in FY, 2017
USD

Revenue (Q2, 2018)

9.1 m

Gross profit (Q2, 2018)

6.5 m

Gross profit margin (Q2, 2018), %

71.5%

Net income (Q2, 2018)

(9.5 m)

EBIT (Q2, 2018)

(9.3 m)

Market capitalization (20-Sep-2018)

130.5 m

Closing stock price (20-Sep-2018)

4.6

Cash (30-Jun-2018)

5.8 m
HTG Molecular Diagnostics's current market capitalization is $130.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

4 m5.1 m14.8 m

Revenue growth, %

27%

Cost of goods sold

3.3 m4.1 m5 m

Gross profit

706.1 k996.8 k9.8 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

790.6 k1 m865.2 k1.9 m913.9 k1.4 m1.8 m4.2 m9.1 m

Cost of goods sold

834.9 k809 k843.5 k933 k1.1 m1.3 m1.2 m1.1 m2.6 m

Gross profit

(44.4 k)201.9 k21.8 k962.8 k(211.1 k)75.9 k523.9 k3 m6.5 m

Gross profit Margin, %

(6%)20%3%51%(23%)6%30%73%71%
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

3.3 m7.5 m10 m

Accounts Receivable

716.2 k1.4 m6.4 m

Current Assets

34.9 m15.1 m17.9 m

PP&E

1.9 m3.3 m3.3 m
Quarterly
USDQ1, 2018Q2, 2018

Cash

20.5 m5.8 m

Accounts Receivable

2.8 m3.5 m

Current Assets

50.2 m46.1 m

PP&E

3.1 m2.9 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(21.4 m)(26 m)(19 m)

Depreciation and Amortization

662.6 k1.5 m1.2 m

Inventories

(746.2 k)(33.2 k)77.2 k

Accounts Payable

(312.3 k)10.1 k1.2 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(6.5 m)(5.2 m)(7 m)(6.9 m)(6.5 m)(5.8 m)

Accounts Payable

879 k1.2 m966.9 k2.2 m1.6 m1.1 m1.2 m1.3 m
USDY, 2018

Financial Leverage

1.8 x
Show all financial metrics
Report incorrect company information

HTG Molecular Diagnostics Online and Social Media Presence

Embed Graph
Report incorrect company information

HTG Molecular Diagnostics News and Updates

HTG Molecular Diagnostics Fulfills First Orders for its Next-Generation Sequencing-Based HTG EdgeSeq Precision Immuno-Oncology Panel

TUCSON, Ariz., Aug. 15, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications, today announced it launched its HTG EdgeSeq Precision Immuno-Oncology Panel and has delivered its first ord…

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a provider of instruments, reagents, and services for molecular profiling applications and Oncologie, Inc. an innovative biotechnology company with operations in Boston and Shanghai, today announ…
Report incorrect company information

HTG Molecular Diagnostics Company Life and Culture

Report incorrect company information